Quantus

Jeil Pharma Holdings

A002620 · KOSPI
₩7,210+3.89%
2026-08-03 close

Jeil Pharma Holdings — pricey right now, or cheap? And what signals are flashing today?

Open the exact grade & valuation bands with Pro →
Loading chart…
Close
AI Insight

Why these signals fired — only backtest-proven edge, told honestly

Why this signalSignal guide

Moving-average alignment
No

No active signal.

Explore this stock further
Review signal, financial and filing context in chat
Explore in chat →

Strong-buy signal — the real recordrecord · not a prediction

Not this one stock, but every strong-buy pick we actually published (Korea market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)

Last 30 sessions
648 picks
Next-day win rate
49.2%
Avg next-day
-0.17%
vs market
+0.72%p

Beat the market on 62.1% of picks (each pick vs its own day’s market average).

Recent publish days (next-day win rate)
07-31 0%07-30 66.7%07-29 0%07-28 45%07-27 20%07-25 36.4%07-21 55.6%07-20 53.8%07-16 53.3%07-15 50%07-14 71.4%07-13 31.2%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.

Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.

Valuation Grades

Relative to 295 건강관리 peers · not investment advice

Pro unlocks the composite grade, 5 factors and sector rank · ₩19,900/mo

Valuation in its own history

PER — · PBR 0.38 — own history (2000-01~) percentiles 7/100 · 98/100

PER7/100
PBR98/100

Higher indicates lower valuation relative to its history (based on earnings and book yields).

Earnings percentiles can fluctuate for cyclical companies (including loss periods), so the book basis is shown alongside. Companies with large share buybacks can have structurally high PBR. Factual information, not investment advice.

Annual dividend

Split-adjusted annual DPS history and available grade axes

Annual dividend per share chart1988: 650원19881989: 34원1990: 26원1991: 32원1992: 32원1993: 3원1994: 26원1995: 26원19951996: 26원1997: 26원1998: 17원1999: 3원2000: 14원20002001: 35원2002: 48원2003: 69원2004: 69원2005: 76원20052006: 80원2007: 69원2008: 73원2009: 42원2010: 69원20102011: 69원2012: 62원2013: 42원2014: 28원2015: 42원20152016: 42원2017: 48원2018: 60원2019: 70원2020: 70원20202021: 70원2022: 65원2023: 50원2024: 50원2025: 50원50원2025
Annual dividend (per share · split-adjusted) · as of 2025
Consistency
A+
Growth
D
Yield
D
Safety
C
Reference indicatorView observed cut rates

Paid 38 consecutive years · Raised 0 consecutive years · Yield 0.69% (based on 2025 payment of 50원) · 3-year growth -8.4%

Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.

Financial safety

Reference indicatorAs of 2024
Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 0.45
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
0.45
Beneish M-Score
-2.80

No statistical flag

Sloan accrual
-6.26%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

3/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score3/9

Profitability

  • Positive ROANot passed
  • Positive OCFPass
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioPass
  • No new sharesNot passed

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityWarning

매출채권 증가율이 매출 증가율의 1.5배 초과 (3기 연속) — 매출 인식 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Cash conversion cycleWarning

현금전환주기(CCC) 3기 연속 확대 — 운전자본 경색·현금 회수 지연 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업이익률 악화 (-1.0% → -7.3%, -6.3%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

KRAs of 2026-08-03

건강관리

This stock is in 건강관리: revenue rank 20 of 290, share 1.3%.

20 / 2901.3%revenue share

Who dominates this industry?

  1. 1삼성바이오로직스7.3%
  2. 2셀트리온5.7%
  3. 3녹십자홀딩스3.5%
  4. 4유한양행3.3%
  5. 5대웅3.1%
  6. 6제일파마홀딩스1.3%

Concentration

DistributedCR3 16.6%
HHI 201290 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
31.61
Direction
확대
Level
넓음
Years
7

Value lens

P90/P10
14
Median P/B
1.47
Level
넓음
n
269

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-7.3%
Interest coverage
-6.4x
Return on equity (ROE)
-16.7%

Operating margin −5pp

Operating loss
Interest coverageBase -6.4x adverse case -10.8x
Return on equity (ROE)Base -16.7% adverse case -34.1%

Revenue −15%

Interest coverage risk
Interest coverageBase -6.4x adverse case -5.4x
Return on equity (ROE)Base -16.7% adverse case -18.6%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -6.4x adverse case -2.8x
Return on equity (ROE)Base -16.7% adverse case -25.2%

Interest coverage limit

Already below the limit by 8.4pp

Interest coverage limit at an operating margin of 1.1%

Interest expense coverage threshold

Financials at a glance

Jeil Pharma Holdings's latest results and balance sheet. The bars track the last three periods.

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.

5%+ major-holding disclosures

  • 한승수73.21%2026-07-15 · 증감 0.00%p

Other stocks held by the same investors

A filing-based shared-holder record, not investment advice.

Recent filings

Jeil Pharma Holdings's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

Signal history (last ~2 years)

Every occurrence on this stock, with the return 20 trading days later. Small sample — a record, not a prediction.

Golden cross×1
26-04-06+0.9%
New MA alignment×2
26-04-28-11.8%26-04-17-3.5%

“·” = fewer than 20 trading days since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.

Like these rules? Run them automatically.

Quantus turns rules like these into backtests and automated trading — same team, free to start.

Quantus Signal · live data · not investment advice · Privacy Policy